Fred Alger Management’s Ocular Therapeutix OCUL Stock Holding History

Fred Alger Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-45,987	Closed	-$185K	–	552
2022 Q2	$185K	Buy	+45,987	New	+$174K	﹤0.01%	429
2021 Q3	–	Sell	-67,584	Closed	-$958K	–	541
2021 Q2	$958K	Sell	67,584 -2,893	-4%	-$44K	﹤0.01%	398
2021 Q1	$1.16M	Sell	70,477 -1,036	-1%	-$20K	﹤0.01%	370
2020 Q4	$1.48M	Sell	71,513 -59,326	-45%	-$881K	﹤0.01%	343
2020 Q3	$996K	Sell	130,839 -9,161	-7%	-$76K	﹤0.01%	344
2020 Q2	$1.17M	Buy	140,000 +105,000	+300%	+$696K	﹤0.01%	337
2020 Q1	$173K	Buy	+35,000	New	+$173K	﹤0.01%	399
2015 Q4	–	Sell	-35,307	Closed	-$496K	–	584
2015 Q3	$496K	Hold	35,307	–	–	﹤0.01%	436
2015 Q2	$743K	Buy	35,307 +5,650	+19%	+$140K	﹤0.01%	442
2015 Q1	$1.25M	Buy	+29,657	New	+$975K	0.01%	486

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Fred Alger Management's OCUL Position: Q3 2022 in Review

Fred Alger Management sold out of Ocular Therapeutix (OCUL) in Q3 2022, closing a stake of 45,987 shares — an estimated $185K sold.

Fred Alger Management first reported a position in OCUL in Q1 2015 and held it in 10 quarters. The position peaked at $1.48M in Q4 2020. 130 funds tracked by Wall St. Rank hold OCUL as of Q3 2022.

Fred Alger Management reported no remaining Ocular Therapeutix position as of Q3 2022 after selling out during the quarter.
Fred Alger Management sold 45,987 Ocular Therapeutix shares in Q3 2022, an estimated $185K.
Fred Alger Management first reported a position in Ocular Therapeutix in Q1 2015 and held it in 10 quarters.
Fred Alger Management's Ocular Therapeutix position peaked at $1.48M in Q4 2020.
130 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2022.

Based on Fred Alger Management's 13F filing for Q3 2022, filed 15 Nov 2022.